Regenerex Pharma (RGPX) sidelines CFO, appoints interim finance chief

Rhea-AI Filing Summary

Regenerex Pharma, Inc. placed its Chief Financial Officer, Kenneth Perry, on paid administrative suspension leave effective March 31, 2026, after the Board cited concerns about compliance with Board directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. The company states that these matters are under review and that no final determinations have been made. Mr. Perry remains an employee and continues to receive his base salary and benefits. Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer on a 90-day initial term with an interim salary of $150,000 annually, bringing extensive public-company auditing and automotive industry financial leadership experience.

Positive

• None.

Negative

• Chief Financial Officer placed on paid administrative suspension leave, with the Board citing concerns involving compliance with Board directives, financial oversight, corporate governance, and financial reporting processes and internal controls, indicating potential risk around financial management and governance pending completion of the company’s review.

Insights

Corporate governance and risk analyst

CFO placed on paid leave amid control concerns; interim finance leadership installed.

The Board of Regenerex Pharma has placed its CFO, Kenneth Perry, on paid administrative suspension leave, removing his duties and authority. The Board cites concerns tied to compliance with its directives, financial oversight, corporate governance, and financial reporting processes and internal controls.

The company notes that these areas are under review and that no final determinations have been made, so the ultimate outcome is still open. Nonetheless, any Board-identified issues around reporting processes and internal controls can be sensitive for stakeholders because they relate directly to financial information quality.

To maintain financial leadership continuity, the Board appointed Don E. Ray as Interim Chief Financial Officer effective April 1, 2026, on a 90-day initial term with an interim salary of $150,000 annually. His background in public-company auditing and automotive finance may help stabilize finance operations while the internal review proceeds.

Key Figures

CFO suspension effective date: March 31, 2026 Interim CFO start date: April 1, 2026 Interim CFO salary: $150,000 annually +1 more

4 metrics

CFO suspension effective date March 31, 2026 Date Kenneth Perry was placed on paid administrative suspension leave

Interim CFO start date April 1, 2026 Effective date of Don E. Ray’s appointment as Interim CFO

Interim CFO salary $150,000 annually Interim salary for Don E. Ray as Interim Chief Financial Officer

Interim CFO initial term 90 days Initial term of Don E. Ray’s interim Chief Financial Officer agreement

Key Terms

administrative suspension leave, corporate governance, financial reporting processes and internal controls, Interim Chief Financial Officer, +1 more

5 terms

administrative suspension leave regulatory

"the Board determined upon review, to place Kenneth Perry, the Company’s Chief Financial Officer, on administrative suspension leave with pay"

corporate governance financial

"based on identified concerns relating to, among other matters, compliance with Board directives, financial oversight, corporate governance"

Corporate governance is the system of rules, roles and oversight that determines how a company is directed and controlled, including the responsibilities of its board, executives and shareholders. Like the steering wheel and map for a car trip, it shapes decisions, sets checks on power and defines who can hold leaders accountable; strong governance reduces risk, builds trust and helps investors judge whether a company is likely to protect capital and deliver reliable returns.

financial reporting processes and internal controls financial

"and the Company’s financial reporting processes and internal controls"

Interim Chief Financial Officer financial

"the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company"

An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.

emerging growth company regulatory

"Emerging growth company [X]"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

0001357878 false 0001357878 2026-03-31 2026-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2026

REGENEREX PHARMA, INC

(Exact Name of Registrant as Specified in its Charter)

Nevada		000-53230		98-0479983
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5348 Vegas Drive #177 Las Vegas, NV		89108
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 761-7479

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] 

Item 5.02 – Departure of Certain Officer; Appointment of certain Officer

On March 31, 2026, the Board of Directors (the “Board”) of Regenerex Pharma, Inc. (the “Company”) determined upon review, to place Kenneth Perry, the Company’s Chief Financial Officer, on administrative suspension leave with pay, effective immediately.

In connection with this action, Mr. Perry's duties, responsibilities, and authority as Chief Financial Officer have been removed and reassigned on an interim basis to an interim CFO designated by the Board.

Mr. Perry will remain an employee of the Company during the period of administrative suspension leave and will continue to receive his base salary and benefits in accordance with his existing employment arrangements, subject to applicable law and Company policy.

The Board’s decision was based on identified concerns relating to, among other matters, compliance with Board directives, financial oversight, corporate governance, and the Company’s financial reporting processes and internal controls. These matters are currently under review by the Company.

The Company emphasizes that the review remains ongoing, and no final determinations have been made with respect to the matters described above.

Appointment of Interim Chief Financial Officer

Effective April 1, 2026, the Board appointed Don E. Ray  to serve as Interim Chief Financial Officer of the Company.  His agreement is an interim appointment with the 90-day initial term.  The interim salary is $150,000 annually. 

Mr. Ray holds a Bachelor of Business Administration in Accounting from the University of Memphis. He began his career at George B. Jones, a national CPA firm specializing in automotive dealerships, where he advanced from staff accountant to Managing Partner prior to its merger into Dixon Hughes Goodman LLP (now Forvis Mazars) in 2002.

At Dixon Hughes Goodman/Forvis Mazars, Mr. Ray served as Co-Managing Partner of the firm’s automotive retail specialty practice, advising public and private companies on accounting, tax, and advisory matters. From 2013 to 2019, he served as Interim Chief Financial Officer and advisor to Price Simms Family Dealerships, an eight-location automotive group in the San Francisco Bay Area representing multiple luxury and mainstream brands .  From 2019 to present Mr. Ray has served of various not-for-profit board of directors.

Earlier in his career, Mr. Ray served as lead auditor for a public company based in Lakeland, Tennessee and has acted as a consultant to several public companies. Most recently, he served as Chief Financial Officer and corporate officer of Diamond Automotive Group, headquartered in Banning, California.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	REGENEREX PHARMA, INC.
	By:	/s/ Greg Pilant
Date: April 2, 2026	Name:	Greg Pilant
	Title:	Chief Executive Officer

FAQ

What action did Regenerex Pharma (RGPX) take regarding its Chief Financial Officer?

Regenerex Pharma placed CFO Kenneth Perry on paid administrative suspension leave effective March 31, 2026. His duties, responsibilities, and authority as Chief Financial Officer were removed and reassigned on an interim basis while the company reviews concerns related to oversight, governance, and reporting processes.

Why was the Regenerex Pharma (RGPX) CFO placed on administrative suspension leave?

The Board cited concerns related to compliance with its directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. These matters are under review, and the company emphasizes that no final determinations have yet been made regarding the issues identified by the Board.

Who is serving as Interim Chief Financial Officer at Regenerex Pharma (RGPX)?

Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer. His interim agreement has a 90-day initial term, and he brings prior experience as a public-company auditor, financial advisor, and automotive industry CFO and corporate officer to the role.

What compensation will the Interim CFO of Regenerex Pharma (RGPX) receive?

Interim CFO Don E. Ray will receive an interim salary of $150,000 annually under his agreement. The appointment is described as an interim role with a 90-day initial term, providing short-term leadership stability for the company’s finance function during the ongoing internal review.

Does Regenerex Pharma (RGPX) still employ its suspended CFO during the review?

Yes. Kenneth Perry remains an employee of Regenerex Pharma during his administrative suspension leave. He continues to receive his base salary and benefits according to his existing employment arrangements, subject to applicable law and company policy, while the company’s review of the identified concerns proceeds.

Has Regenerex Pharma (RGPX) reached any final conclusions about the CFO-related concerns?

No. The company states that the review of concerns involving Board directives, financial oversight, corporate governance, and financial reporting processes and internal controls is ongoing. It explicitly notes that no final determinations have been made regarding these matters at this time.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 SCHEMA DOCUMENT 3.0 KB
• EX-101 LABELS LINKBASE DOCUMENT 12.8 KB
• EX-101 PRESENTATION LINKBASE DOCUMENT 7.9 KB